Posted by Michael Wonder on 18 Jan 2023
Voxelotor for the treatment of patients with sickle cell disease
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using voxelotor in the NHS in England.
Voxelotor is not recommended, either as monotherapy or combination with hydroxyurea, for the treatment of patients 12 years of age and older with haemolytic anaemia caused by sickle cell disease.
